- Published at
- by financialpost.com
neutral
neutral
News for Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ)
- Published at
- by marketscreener.com
mixedmixedHUTCHMED Announces Changes to Board of Directors and Technical Committee
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical CommitteeHONG KONG and SHANGHAI, China and FLORHAM PARK, N.J.,...- Published at
- by globenewswire.com
mixedmixedRich Insights Into The Robust Osteoporosis Clinical Trials Pipeline Analysis By DelveInsight
Increasing prevalence and rising geriatric population are the main factors driving the development of novel drugs for the treatment of osteoporosis. Major...- Published at
- by vcnewsdaily.com
positivepositiveSalubris Biotherapeutics Inks $32M Funding
GAITHERSBURG, MD, Salubris Biotherapeutics, a clinical-stage biotechnology company, has received $32M in financing from Salubris Pharmaceuticals.- Published at
- by becomeabetterinvestor.net
positivepositiveWorld Class Benchmarking of Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Company Limited (002294 SZ): Profitable Growth rank of 8 was down compared to the prior period’s 6th rank.